Research Reports | Market Assessment
April 2019

Multiple Myeloma | Current Treatment | US | 2016

The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatment of this disease, and the treatment algorithms for multiple myeloma continue to evolve, driven by the 2015 approval of several novel, high-priced therapies with new mechanisms of action. This analysis provides insight on current and anticipated use of approved therapies for multiple myeloma and on hematologist-oncologists’ perception of these therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports